Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer
patients with advanced disease.
The primary evaluation criterion is clinical benefit response.